Background-Published meta-analyses comparing primary percutaneous coronary intervention with fibrinolytic therapy in patients with ST-segment-elevation myocardial infarction include only randomized controlled trials (RCTs). We aim to obviate the limited applicability of RCTs to real-world settings by undertaking meta-analyses of both RCTs and observational studies. Methods and Results-We included all RCTs and observational studies, without language restriction, published up to May 1, 2008. We completed separate bayesian hierarchical random-effect meta-analyses for 23 RCTs (8140 patients) and 32 observational studies (185 900 patients). Primary percutaneous coronary intervention was associated with reductions in short-term (Յ6-week) mortality of 34% (odds ratio, 0.66; 95% credible interval, 0.51 to 0.82) in randomized trials, and 23% lower mortality (odds ratio, 0.77; 95% credible interval, 0.62 to 0.95) in observational studies. Primary percutaneous coronary intervention was associated with reductions in stroke of 63% in RCTs and 61% in observational studies. At long-term follow-up (Ն1 year), primary percutaneous coronary intervention was associated with a 24% reduction in mortality (odds ratio, 0.76; 95% credible interval, 0.58 to 0.95) and a 51% reduction in reinfarction (odds ratio, 0.49; 95% credible interval, 0.32 to 0.66) in RCTs. However, there was no conclusive benefit of primary percutaneous coronary intervention in the long term in the observational studies. Conclusions-Compared with fibrinolytic therapy, primary percutaneous coronary intervention was associated with short-term reductions in mortality, reinfarction, and stroke in ST-segment-elevation myocardial infarction. Primary percutaneous coronary intervention was associated with long-term reductions in mortality and reinfarction in RCTs, but there was no conclusive evidence for a long-term benefit in mortality and reinfarction in observational studies. (Circulation. 2009;119:3101-3109.) The online-only Data Supplement is available this article at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.108.793745/DC1.
S everal randomized controlled trials (RCTs) show that primary percutaneous coronary intervention (PCI) is associated with reductions in mortality, reinfarction, and stroke compared with fibrinolytic therapy. However, many aspects of reperfusion therapy might not be optimally assessed in RCTs. First, the benefit of primary PCI may not be replicable under suboptimal conditions such as at low-volume and less expert PCI centers, 24 outside regular working hours, or after lengthy interhospital transfer. Second, use of rescue or elective PCI was limited (Ͻ20%) in several RCTs, 1,8,11,12,14,16-17,20 -22 whereas rescue or elective PCI is generally performed as indicated in the real world. Furthermore, patients with ST-segment-elevation myocardial infarction (STEMI) enrolled in RCTs are generally younger with fewer comorbid conditions than patients in the real world. 25 Therefore, extrapolation of the safety and effectiveness of primary PCI and fibrinolytic therapy observed in RCTs to the real-world STEMI population might not be entirely appropri-ate. Previous meta-analyses included only RCTs. We aim to obviate the limitations of these analyses by examining results from observational studies in addition to those of RCTs. We also include recently published data from several RCTs that were not considered in previous meta-analyses.
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Methods
Search Strategy
We retrieved RCTs and observational studies that compared primary PCI and fibrinolytic therapy in STEMI from the following databases: BIOSIS, Cinahl, Embase, PubMed, Web of Science, Cochrane Library, health technology assessment agencies, and Current Contents (up to May 1, 2008) (no language restriction). We used the following keywords: angioplasty, fibrinolysis, thrombolysis, fibrinolytic therapy, acute myocardial infarction, percutaneous coronary intervention, reperfusion therapy, coronary stent, treatment, and management. In addition, we manually searched the references of published articles to ensure identification of all published STEMI trials.
Inclusion Criteria
Only studies that used full-dose commercially approved fibrinolytic therapy such as streptokinase, urokinase, and fibrin-specific agents like tissue plasminogen activators, tenecteplase, and reteplase were retained for analysis. We retained only studies that reported results for both treatment arms (primary PCI and fibrinolytic therapy). Finally, the observational studies retained had to fulfill the quality requirements suggested by Concato et al, 26 including inclusion of concurrent rather than historical controls, clearly defined inclusion criteria, and defined time of entry into the study.
Exclusion Criteria
We excluded studies that used facilitated PCI, experimental fibrinolytic agents (other than the agents listed above), or intracoronary administration of fibrinolytic therapy, as well as studies that enrolled mainly patients with contraindications to either fibrinolytic therapy or primary PCI. For studies that compared primary PCI, facilitated PCI, and fibrinolytic therapy, 2, 16, 22 we excluded patients who underwent facilitated PCI from the analysis. We also excluded studies presented at conferences or published only as abstracts or conference proceedings because detailed appraisal of the methodology and potential biases was not possible.
End Points
All end points were analyzed as distinct events rather than as a composite end point comprising multiple events. The latter approach can be suboptimal because of equal contributions to the composite end point by end points with unequal clinical relevance. 27 Intracranial bleeding was compiled as stroke and therefore excluded from major bleeding. Major bleeding included all hemorrhagic complications that were severe or life-threatening or required transfusion. Short-term end points included all events up to 6 weeks after the index STEMI. Long-term end points included all events that occurred at least 1 year after the STEMI.
Study Quality
We critically appraised the quality of the RCTs and observational studies in conformity with the CONSORT (CONsolidated Standards of Reporting Trials) and MOOSE (Meta-analysis Of Observational Studies in Epidemiology) guidelines. 28, 29 We elected not to use scales to evaluate the quality of each study because this approach is controversial with potentially inappropriate adjustment of the treat-ment effects and marked variation in treatment effects depending on the scale used. 30 
Data Extraction
Two reviewers (T.H. and S.P.) independently selected studies for inclusion, extracted data, and evaluated the quality of each study. Disagreements were resolved by consensus between the 2 reviewers. The first author (T.H.) had full access to and takes full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Statistical Analysis
We completed separate meta-analyses for each end point for RCTs and observational studies separately. Because it was unlikely that the effects of primary PCI and fibrinolytic therapy would be similar across studies as a result of differences in study design and patient characteristics, a fixed-effect model was not appropriate. Therefore, we used a bayesian hierarchical random-effects model to take intertrial variation in treatment effects into account. 31 In our models, the total number of events within each group in each trial was modeled as a binomial random variable. The models allowed for the probability of an event to vary both between treatment arms within each study and between studies. The logarithms of the odds ratios (ORs) were assumed to have a normal distribution. The mean of the normal distribution of the logarithm of the ORs across studies represented the average effect across studies, and the variance represented the variability between studies.
Bayesian analysis allows the integration of new information into existing knowledge. Substantive prior knowledge can be included into bayesian analysis through the choice of a prior distribution. Because we wanted our results (ie, the posterior distributions) to primarily reflect data from previous studies, we selected noninformative prior distributions for all parameters of interest. These included normal densities (mean, 0; ϭ0.00001 [variance of 10 5 ]) for the logarithm of the ORs and (ϭuniform on the interval [0,2]). Sensitivity analyses varying the prior distributions for a sigma and gamma prior distribution (0.001, 0.001) did not change posterior inferences substantially. Therefore, our estimates of ORs and 95% credible intervals (95% CrIs) were not greatly affected by our a priori choices.
Inferences were calculated with a Gibbs sampler algorithm as implemented through WinBUGS software (version 1.4.2, MRC Biostatistics Unit, Cambridge, UK). To ensure convergence of the Gibbs sampler algorithm, 3 Markov Monte Carlo chains were run, and convergence was assessed after 60 000 iterations. The final summary statistics were based on 120 000 iterations, 100 000 of them for burn-in. The forest plots were completed with R 2.4.1 software (www.r-project.org/).
We examined for potential publication bias with funnel plots, fail-safe N, and trim and fill (www.meta-analysis.com). Sensitivity analyses were performed with nonbayesian statistical methods, random-effects restricted-maximum-likelihood method (SAS 8.0, SAS Institute Inc, Cary, NC), and random-effects model (DerSimonian-Laird estimator) (NCSS 2007, NCSS, Kaysville, Utah). The results were essentially similar to those obtained by bayesian hierarchical meta-analyses. Figure 1 describes the selection of studies for the analysis. Twenty-three RCTs 1-23 and 32 observational studies 24, were retained. The mean age of patients enrolled ranged from 57 to 80 years in the RCTs and from 57 to 91 years in the observational studies. Two RCTs 2,4 and 7 observational studies 23, 35, 39, 49, 61, 62 reported prehospital administration of fibrinolytic therapy. Fibrin-specific agents were used primarily in 16 RCTs 1-4,6 -12,14,15,19,20,22 and 11 observational studies 24 (Tables I and II of the online-only Data Supplement).
Results
Primary PCI was associated with an Ϸ34% short-term reduction in mortality (OR, 0.66; 95% CrI, 0.51 to 0.82) in RCTs ( Figure 2) and an Ϸ23% lower mortality in observational studies (OR, 0.77; 95% CrI, 0.62 to 0.95; Figure 3 ). There was no conclusive difference in mortality in the meta-analysis of observational studies that used prehospital fibrinolytic therapy. 23, 35, 39, 49, 61, 62 An estimate of the difference in mortality between primary PCI and prehospital fibrinolytic therapy could not be done with certainty because only 2 RCTs used prehospital fibrinolysis. 2, 4 In RCTs, primary PCI was associated with a 24% reduction in long-term mortality (OR, 0.76; 95% CrI, 0.58 to 0.95; Figure 4 ). However, in observational studies, there was no conclusive difference between the 2 reperfusion strategies in long-term mortality (OR, 0.88; 95% CrI, 0.68 to 1.18; Figure 5 ). Reductions in short-term reinfarction of 65% and 53% were observed in RCTs and observational studies, respectively ( Table 1 ). An Ϸ51% reduction associated with primary PCI in long-term reinfarction was noted in RCTs, whereas there was no conclusive difference in reinfarction between treatments in the observational studies (Table 1) . Primary PCI was associated with a 60% reduction in stroke in both RCTs and observational studies (Table 1) . Although inconclusive because of the limited number of studies available, the risk estimates were consistent with a possible increase in major bleeding associated with primary PCI (Table 1) .
Absolute risk reductions in short-term mortality with primary PCI were Ϸ2.2% (95% CrI, 1.3 to 3.2) in RCTs and 1.1% (95% CrI, 0.4 to 1.5) in observational studies ( Table 2) . Absolute risk reductions in short-term reinfarction were Ϸ4.5% in RCTs and 2.9% in observational studies. Absolute reductions in stroke were Ϸ1.2% in RCTs and 0.6% in observational studies. At long-term follow-up, primary PCI was associated with absolute reductions in long-term mortality of 3.5% (95% CrI, 0.7 to 6.4) and in reinfarction of 3.4% (95% CrI, 1.6 to 5.9) in RCTs, without conclusive evidence for reductions in long-term mortality and reinfarction in observational studies.
The number needed to treat to prevent 1 short-term death with primary PCI was 45 in RCTs and 91 in observational studies ( Table 2 ). The number needed to treat to prevent 1 long-term death was 29 in RCTs. More specifically, for 100 patients treated with primary PCI, in conditions similar to those in the RCTs, there would be 2 deaths and 5 reinfarctions prevented in the short term and 3 deaths and 5 reinfarctions prevented in the long term. For 100 patients treated with primary PCI, in conditions similar to those in observational studies, 1 death and 3 reinfarctions would be prevented in the short term, with no conclusive long-term benefit. For stroke reduction, Ϸ1 event would be prevented in 100 patients treated with primary PCI in conditions similar to those in the RCTs, whereas only 1 stroke would be prevented in Ϸ200 patients treated with primary PCI in conditions similar to those in the observational studies.
Discussion
Our meta-analyses improve on previous systematic reviews by including short-term results from 3 recent RCTs 2,19 -21 and including observational studies. 28, Our study incorporates events at Ն1 year and includes long-term results from 5 RCTs that were not considered in earlier reviews (data at 1 year from Dobrycski et al 21 and the PRAGUE [Primary Angiography in patients transferred from General community hospitals to specialized PTCA Units with or without Emergency thrombolysis]-1 trial, 63 at 2 years from the PAMI [Primary Angioplasty in Myocardial Infarction]-1 trial, 64 
at 3 years from the DANAMI [DANish trial in Acute Myocardial
Infarction]s-2, 65 at 5 years from the PRAGUE-2 study, 66 and at 8 years from the Zwolle Study 67 ). Given the marked heterogeneity in study designs and patient populations across studies, our random-effects hierarchical bayesian meta-analyses are more appropriate models 37 than the fixed-effects models.
Several biases may affect the internal validity of RCTs, including lack of central randomization and a blinded adjudication committee, both of which may affect the integrity of randomization and objective ascertainment of end points. Only 10 RCTs specified use of central randomization. 1, [3] [4] [5] 10, 16, 17, 20, 22, 23 Outcome adjudication by a blinded committee was mentioned in only 10 RCTs. 1,2,4 -6,9 -12,15 Observational studies are susceptible to many biases, including selection and confounding biases. Observational studies that exclude patients who did not undergo a planned primary PCI may be subject to selection bias. Only 3 observational studies included all patients assigned to primary PCI regardless of whether they underwent successful PCI. 24, 38, 39 Confounding bias may occur in observational studies when patient characteristics affect the treatment received and the outcomes. Patients who received fibrinolytic therapy were older than patients who received primary PCI in 3 observational studies. 34, 35, 40 There were more patients with anterior STEMI, heart failure, or cardiogenic shock in the primary PCI group in 6 studies 34,39 -41,45,48 and in patients who received fibrinolytic therapy in 2 studies. 33, 35 Primary PCI patients received more optimal medical therapy and coronary intervention and were more likely to be treated at high-volume hospitals than patients who received fibrinolytic therapy. 35, 41, 44, 48 The internal validity of both RCTs and observational studies may be affected by differential loss to follow-up in the treatment groups. Except for 1 study 64 that reported high attrition (16%), long-term follow-up was almost complete in most RCTs. Five observational studies reported at least 95% long-term follow-up. 33, 34, 39, 45, 62 Our risk estimates remained virtually unchanged when restricted to studies with optimal follow-up.
The applicability of results from RCTs to the real-world setting is generally limited. Several RCTs excluded elderly patients, 7, 13, 14, 21, 22 patients with renal disease, 3,4,10,12 those in cardiogenic shock, 1, 4, 7, 9, 14, 19, 22 patients with Killip class Ն2 8, 18, 20, 23 and patients with left bundle-branch block, 1, 6, 8, 18, 21 so their results may not be applicable to these high-risk patient groups. The long-term attenuation of the early reductions in mortality and reinfarction associated with primary PCI may be due to optimal long-term medical therapy that may have delayed the long-term progression of coronary artery disease equally in both treatment arms. The reduced magnitudes of risk reductions associated with primary PCI in observational studies compared with those in RCTs might reflect real-world practice. Greater use of in-hospital PCI (Ն30%) after fibrinolytic therapy in observational studies 24, 35, 41, 43, 44, 55, 62 may partially explain the smaller reductions in short-term mortality and reinfarction associated with primary PCI. In the real world, primary PCI also may be less successful when per-formed in less-than-optimal conditions. In observational studies, the lack of conclusive long-term benefits with primary PCI may be explained by optimal medical therapy and/or the judicious use of coronary interventions in patients who received fibrinolytic therapy.
Study Limitations
These meta-analyses have several limitations that warrant mention. First, the comparison of primary PCI with prehospital fibrinolysis could not be ascertained with certainty because of the small number of studies that used this reperfusion strategy. The efficacy and safety of prehospital fibrinolysis compared with primary PCI may be better evaluated in future large studies. Second, the greater use of thienopyridines in primary PCI than in the fibrinolytic therapy arm might have partially confounded the results. The mortality difference between primary PCI and fibrinolytic therapy may be attenuated with more systematic administration of thienopyridines after fibrinolytic therapy. On the other hand, recent technological advances in primary PCI may further increase the mortality and reinfarction benefits associated with primary PCI. Third, the validity of our meta-analysis of long-term mortality in observational studies was potentially limited by the lack of long-term data from the large observational NRMI-3/4 studies. 56 Nonetheless, it would be unlikely that long-term data from NRMI-3/4 would modify our results because there was no short-term mortality difference between the 2 treatment arms in this study. Fourth, our estimate of long-term mortality may have been influenced by the large observational RIKS-HIA study. 35 However, sensitivity analyses excluding the RIKS-HIA study showed essen- tially similar results with no conclusive difference in long-term mortality between the 2 treatment arms. Finally, reports with positive findings are more likely to be reported, published, and cited. 68 However, the lack of asymmetry in the funnel plots suggests that we did not miss important negative studies.
Conclusions
Compared with fibrinolytic therapy in STEMI, primary PCI was associated with short-term reductions in mortality, reinfarction, and stroke in both RCTs and observational studies and with long-term reductions in reinfarction and mortality in RCTs.
There was no conclusive difference in long-term mortality and reinfarction between primary PCI and fibrinolytic therapy in the observational studies reviewed. The potential benefit of prehospital fibrinolysis compared with primary PCI cannot be reliably ascertained from the present review. NA indicates not applicable because there was no conclusive benefit with primary PCI.
